‘Reassuring’: Omitting full axillary dissection does not worsen survival in breast cancer

CHICAGO — Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from the randomized SENOMAC trial, presented at ASCO Annual Meeting, showed patients who did not undergo completion axillary lymph node dissection (cALND) after a sentinel lymph node biopsy